MammaPrint® is a test that helps show whether some estrogen receptor-positive (ER-positive), HER2-negative breast cancers are likely to metastasize (spread to other organs).
Every cell in your body has genes that contain the blueprints (genetic code) for your body. Similarly, every cell in a breast tumor has genes. These genes contain the blueprints for the cancer.
Tumor profiling (using gene expression profiling tools) gives information about the genes in cancer cells. You may also hear the terms genomic testing and molecular profiling.
MammaPrint is a tumor profiling test.
MammaPrint tests a sample of the tumor (removed during a biopsy or surgery) for a group of 70 genes.
The results of the MammaPrint test help predict the chance of metastasis.
If MammaPrint results show a fairly high risk of metastasis, a more aggressive treatment plan that includes both hormone therapy and chemotherapy may be advised [50-51].
If MammaPrint results show a low risk of metastasis, the use of hormone therapy alone may be considered.
In this way, MammaPrint may help some people avoid chemotherapy and its side effects.
MammaPrint helps predict the chance of metastasis for some breast cancers at high clinical risk of recurrence (based on estrogen receptor status, HER2 status, tumor grade, lymph node status and tumor size).
MammaPrint can be used for high clinical risk breast cancers that are all of the following [50-51]:
Breast Cancer Prognosis
Triple Negative Breast Cancer
The Role of Genetic, Genomic and Tumor Profiling Tests
Research Fast Facts
HER2 and Breast Cancer
1-877 GO KOMEN(1-877-465-6636)